Lancet trial: weekly semaglutide cut heavy drinking days by 41% in patients with AUD and obesity

The second piece of high-quality randomized evidence on GLP-1 receptor agonists for alcohol use disorder is now public. A trial published in The Lancet — Copenhagen University Hospital–led, 108 treatment-seeking adults with both AUD and obesity, 26 weeks of weekly subcutaneous semaglutide vs. placebo — found a 41.1% reduction in heavy drinking days, a 13.7-percentage-point larger reduction than placebo. Roughly 12 fewer heavy-drinking days per month, against 8 in the placebo arm. USNews flagged the result on May 5, and Medscape’s clinical write-up frames it as the long-awaited confirmation of the NIAAA CBT-augmentation signal we covered last week.

What this changes — and what it doesn’t

This is the trial the field has been waiting for: properly powered, placebo-controlled, published in a top-tier journal, with a clinically meaningful endpoint (heavy drinking days, not just self-reported craving). It does not replace acamprosate, naltrexone, or disulfiram — the existing AUD pharmacotherapy stack — but it does open a fourth track that uniquely targets people with AUD and metabolic comorbidities, who are a large slice of the real-world AUD population. The trial’s eligibility criteria specifically required comorbid obesity, so generalization to AUD without obesity is the next open question. Off-label prescribing of GLP-1s for drinking is already happening; this evidence base will accelerate it. The thing to watch is insurance coverage policy, which currently treats GLP-1s as obesity drugs and not addiction drugs.

Why this matters for people in recovery

If you are working with a clinician on an alcohol-related goal and you are also being prescribed a GLP-1 for weight or diabetes, this is information your treatment team should know. It is also a reasonable thing to raise with a primary care provider if both conditions apply to you. As always, medication is one piece — therapy, peer support, family involvement, and life-context matter at least as much. See Rize’s alcohol resources for a fuller picture.